MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534879 | Name: N 0861

Description:

WARNING: This product is for research use only, not for human or veterinary use.

N 0861 is an adenosine receptor antagonist.

Chemical Structure

N 0861
N 0861
CAS#141696-90-4

Theoretical Analysis

MedKoo Cat#: 534879

Name: N 0861

CAS#: 141696-90-4

Chemical Formula: C13H17N5

Exact Mass: 243.1484

Molecular Weight: 243.31

Elemental Analysis: C, 64.17; H, 7.04; N, 28.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
N 0861; N-0861; N0861
IUPAC/Chemical Name
9H-Purin-6-amine, N-bicyclo(2.2.1)hept-2-yl-9-methyl-, endo-(+-)-
InChi Key
MTQYIGCUBBMQCJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H17N5/c1-18-7-16-11-12(14-6-15-13(11)18)17-10-5-8-2-3-9(10)4-8/h6-10H,2-5H2,1H3,(H,14,15,17)
SMILES Code
CN1C=NC2=C(NC3C(C4)CCC4C3)N=CN=C12
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 243.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bertolet BD, Belardinelli L, Franco EA, Nichols WW, Kerensky RA, Hill JA. Selective attenuation by N-0861 (N6-endonorboran-2-yl-9-methyladenine) of cardiac A1 adenosine receptor-mediated effects in humans. Circulation. 1996 May 15;93(10):1871-6. doi: 10.1161/01.cir.93.10.1871. PMID: 8635266. 2: Glover DK, Ruiz M, Sansoy V, Barrett RJ, Beller GA. Effect of N-0861, a selective adenosine A1 receptor antagonist, on pharmacologic stress imaging with adenosine. J Nucl Med. 1995 Feb;36(2):270-5. PMID: 7830130. 3: Shryock JC, Travagli HC, Belardinelli L. Evaluation of N-0861, (+-)-N6-endonorbornan-2-yl-9-methyladenine, as an A1 subtype-selective adenosine receptor antagonist in the guinea pig isolated heart. J Pharmacol Exp Ther. 1992 Mar;260(3):1292-9. PMID: 1545393. 4: Barrett RJ, Droppleman DA, Wright KF. N-0861 selectively antagonizes adenosine A1 receptors in vivo. Eur J Pharmacol. 1992 May 27;216(1):9-16. doi: 10.1016/0014-2999(92)90202-f. PMID: 1526257. 5: Yasuda SU, Nagashima S, Douyon E, Benton RE, Woosley RL, Barbey JT. Adenosine A1-receptor occupancy predicts A1-receptor antagonist effects of N-0861. Clin Pharmacol Ther. 1998 Nov;64(5):536-41. doi: 10.1016/S0009-9236(98)90136-9. PMID: 9834045. 6: Martin PL, Potts AA, Sykes AM, McKenna DG. (+-)-N6-endonorbornan-2-yl-9-methyladenine (N-0861) and its enantiomers: selective antagonists of A1-adenosine receptors in guinea pig isolated atria. J Pharmacol Exp Ther. 1993 Apr;265(1):201-6. PMID: 8474007. 7: Sidi A, Wesley R, Barrett R, Rush W, Belardinelli L. Cardiovascular effects of a non-xanthine-selective antagonist of the A1 adenosine receptor in the anaesthetised pig: pharmacological and therapeutic implications. Cardiovasc Res. 1994 May;28(5):621-8. doi: 10.1093/cvr/28.5.621. PMID: 8025906. 8: Wesley RC Jr, Porzio D, Sadeghi M. Effect of selective A1 adenosine receptor antagonism of postdefibrillation cardiovascular depression: evidence for an antiadrenergic role of endogenous adenosine. Cardiovasc Res. 1993 Jan;27(1):129-33. doi: 10.1093/cvr/27.1.129. PMID: 8458023. 9: Belardinelli L, Shryock JC, Zhang Y, Scammells PJ, Olsson R, Dennis D, Milner P, Pfister J, Baker SP. 1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells. J Pharmacol Exp Ther. 1995 Dec;275(3):1167-76. PMID: 8531078. 10: Martin PL, Wysocki RJ Jr, Barrett RJ, May JM, Linden J. Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J Pharmacol Exp Ther. 1996 Feb;276(2):490-9. PMID: 8632314. 11: Shryock JC, Ozeck MJ, Belardinelli L. Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Mol Pharmacol. 1998 May;53(5):886-93. PMID: 9584215. 12: Martin PL, May JM. Identification and functional characterization of A1 and A2 adenosine receptors in the rat vas deferens: a comparison with A1 receptors in guinea pig left atrium and A2 receptors in guinea pig aorta. J Pharmacol Exp Ther. 1994 Jun;269(3):1228-35. PMID: 8014866. 13: Barrett RJ, Wright KF. A selective adenosine A1 receptor antagonist attenuates renal dysfunction during controlled hypotension with adenosine in rats. Anesth Analg. 1994 Sep;79(3):460-5. doi: 10.1213/00000539-199409000-00010. PMID: 8067549. 14: Fahim M, Mustafa SJ. Evidence for the presence of A(1) adenosine receptors in the aorta of spontaneously hypertensive rats. Br J Pharmacol. 2001 Dec;134(8):1760-6. doi: 10.1038/sj.bjp.0704433. PMID: 11739253; PMCID: PMC1572910. 15: Kodani E, Bolli R, Tang XL, Auchampach JA. Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptor. Basic Res Cardiol. 2001 Sep;96(5):487-96. doi: 10.1007/s003950170031. PMID: 11605996. 16: Takano H, Bolli R, Black RG Jr, Kodani E, Tang XL, Yang Z, Bhattacharya S, Auchampach JA. A(1) or A(3) adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res. 2001 Mar 16;88(5):520-8. doi: 10.1161/01.res.88.5.520. PMID: 11249876. 17: Song Y, Thedford S, Lerman BB, Belardinelli L. Adenosine-sensitive afterdepolarizations and triggered activity in guinea pig ventricular myocytes. Circ Res. 1992 Apr;70(4):743-53. doi: 10.1161/01.res.70.4.743. PMID: 1551200. 18: Barrett RJ. Realizing the potential of adenosine-receptor-based therapeutics. Proc West Pharmacol Soc. 1996;39:61-6. PMID: 8895971. 19: Giannella E, Mochmann HC, Levi R. Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Circ Res. 1997 Sep;81(3):415-22. doi: 10.1161/01.res.81.3.415. PMID: 9285644. 20: Meester BJ, Shankley NP, Welsh NJ, Wood J, Meijler FL, Black JW. Pharmacological classification of adenosine receptors in the sinoatrial and atrioventricular nodes of the guinea-pig. Br J Pharmacol. 1998 Jun;124(4):685-92. doi: 10.1038/sj.bjp.0701891. PMID: 9690860; PMCID: PMC1565446.